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Abstract
Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase which promotes cell proliferation and survival, is
abnormally overexpressed in numerous tumors of epithelial origin, including colorectal cancer (CRC). EGFR monoclonal
antibodies have been shown to increase the median survival and are approved for the treatment of colorectal cancer.
Histone deacetylases (HDACs), frequently overexpressed in colorectal cancer and several malignancies, are another
attractive targets for cancer therapy. Several inhibitors of HDACs (HDACi) are developed and exhibit powerful antitumor
abilities. In this study, human colorectal cancer cells treated with HDACi exhibited reduced EGFR expression, thereby
disturbed EGF-induced ERK and Akt phosphorylation. HDACi also decreased the expression of SGLT1, an active glucose
transporter found to be stabilized by EGFR, and suppressed the glucose uptake of cancer cells. HDACi suppressed the
transcription of EGFR and class I HDACs were proved to be involved in this event. Chromatin immunoprecipitation analysis
showed that HDACi caused the dissociation of SP1, HDAC3 and CBP from EGFR promoter. Our data suggested that HDACi
could serve as a single agent to block both EGFR and HDAC, and may bring more benefits to the development of CRC
therapy.
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Introduction
EGFR (also known as ErbB-1/HER1), which belongs to the
ErbB family of receptor tyrosine kinases, comprises an extracel-
lular ligand-binding domain, a single hydrophobic transmembrane
domain and a cytoplasmic tyrosine kinase-containing domain [1].
Ligand binding induces homo- or hetero-dimerization of receptor
and subsequent activation of the pathways including Ras/Raf/
MEK/ERK and PI3K/PDK1/Akt [1]. Most of colorectal cancer
(CRC) is characterized with overexpression of epidermal growth
factor receptor (EGFR) and predicted with high risk of metastasis
and recurrence [2]. Targeting EGFR seems to be a promising
approach for the CRC treatment. Indeed, cetuximab, a human-
mouse chimeric IgG1 antibody binds to the external domain of the
EGFR, has been approved by FDA in 2004 for the treatment of
metastatic colorectal cancer [3]. After that, a fully humanized
antibody, panitumumab, is also approved to treat CRC [4].
However, accumulating evidences demonstrate that the effects of
targeting EGFR in colorectal cancer are largely limited due to the
status of KRAS mutation [5]. The KRAS mutants bypass EGFR
to activate the Ras/Raf/MEK/ERK signals, and significantly
weaken the therapeutic effect of cetuximab [6]. Examination of
KRAS status is now a prerequisite for the use of cetuximab [7].
Although ,60% of CRC patients expressed wild-type KRAS but
only half of them benefits from cetuximab. Therefore, the KRAS
status is not the only determinant for the efficacy of EGFR target
therapy [8]. Therefore, treatment with a broad spectrum of
genetic backgrounds is urgently needed and would benefit most
patients irresponsive to cetuximab-based therapies.
Although EGFR is a receptor tyrosine kinase and delivers
signals after ligand conjugation, its prosurvival effect can be
independent to kinase activity. For example, mice lacking EGFR
are embryonic lethal but those harboring kinase-inactive mutants
only exhibit some epithelial defects [9,10]. In addition, loss of
EGFR kinase activity decelerates cell proliferaiton but loss of its
expression ruins the glucose uptake and leads to cell death [11–
13]. Therefore, inhibition of EGFR expression may be a better
strategy for CRC therapy.
Histone deacetylases (HDACs) which removes the acetyl groups
from histone to silence the gene transcription are highly expressed
in various tumors [14,15]. HDACs have become one of the
emerging targets for cancer therapy, and HDAC inhibitors
(HDACi) show promising anticancer activities [15]. Among
various HDACi, SAHA (Vorinostat) had been successfully
approved for the treatment of cutaneous T cell lymphoma
(CTCL). HDAC family can be subdivided into four classes and
the class I HDACs, which includes HDAC1, HDAC2, HDAC3
and HDAC8, have been reported to be highly expressed in colon
cancer [16]. The pro-proliferative effects of HDACs are connected
to the transcriptional repression of cdk-inhibitor, p21, and
knockdown of HDAC 1, 2 and 3 reduced the growth of several
colon cancer cells [17]. Therefore, HDAC may serve as a potential
target for CRC therapy, and SAHA had entered clinical trials for
the treatment of CRC [18].
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18087In this study, we demonstrated that the EGF signaling in KRAS
mutant cell lines, HCT116 and SW480, was disrupted by HDACi
through transcriptional repression of EGFR expression, indicating
that HDACi served as a single agent to block EGFR and HDAC
simultaneously. Loss of EGFR partially contributed to the
cytotoxic effect of HDAC inhibitors. In addition, the expression
of SGLT1, an active glucose transporter which is stabilized by
EGFR, was also decreased by HDACi and led to the reduction of
glucose uptake in colon cancer cells. The mechanism underlying
the transcriptional repression of EGFR by HDACi was involved
with the histones hypoacetylation and the dissociation of SP1,
HDAC3 and CBP from EGFR promoter. Our data suggested that
HDACi could serve as a single agent to concurrently block both
EGFR and HDAC, and may bring benefits to the CRC patients
with a broader range of genetic backgrounds.
Materials and Methods
Ethics Statement
All patient-derived specimens were collected and archived
under protocols approved by Institutional Research Board of
National Taiwan University Hospital and supported by the
National Science Council, Taiwan. A full verbal explanation of
the study was given to all participants. They consented to
participate on a voluntary basis.
Materials
TSA was purchased from Sigma and SAHA were obtained
from Merck. The Myc-tagged HDAC1, 2 and 3 were provided by
Dr. WM Yang (NCHU, Taiwan). Antibodies specific for EGFR,
p21, HDAC3, and actin were purchased from Santa Cruz
Biotechnology. Anti–Ac-histone H3, H4, and Sp1 antibodies were
obtained from Upstate. Anti-SGLT1 antibody was purchased
from Abcam.
Cell culture
HCT-116 (from Van Dyke MW, M.D. Anderson) and SW480
(from TH Leu, NCKU) human colon carcinoma cells were
cultured in DMEM supplemented with 10% fetal bovine serum;
A431 (human epidermoid carcinoma cells) and MDA-MB-468
(human breast adenocarcinoma cells) obtained from ATCC were
maintained in RPMI supplemented with 10% FCS.
RNA isolation, RT-PCR and real time PCR
Total RNA was isolated from HCT116 cell using Trizol reagent
(Life Technology). Reverse transcription reaction was performed
using 2 mg of total RNA, reverse transcribed into cDNA using
oligo dT primer. cDNA was subjected to RT-PCR and amplified
30 cycles using two oligonucleotide primers derived from
published EGFR or GAPDH sequence, including 59- TGGAGC-
TACGGGGTGACCGT-39 and 5’-GGTTCAGAGGCTGAT-
TGTGAT-39 (EGFR), 59-AAGCCCATCACCATCTTC-CAG-
39 and 59-AGGGGCCATCCACA-GTCTTCT-39(GAPDH) and
59-TGAC-GGGGTCACCCACACTGTGCCCATCTA-39 and
59-CTAGAAGCATTTGCG-GGGACGATGGAGGG-39(Actin).
The PCR products were subjected to 1.2% agarose gel
electrophoresis and visualized by ethidium bromide staining. Real
time PCR was performed with cDNA samples using the ABI Prism
7900 Sequence Detection System (Applied Biosystems, Foster
City, CA). Primers were as follows: EGFR (forward primer, 59-
TTCCTCCCAGTGCCTGAAT-39 reverse primer, 59-GGTT-
CAGAGGCTGAT-TGTGAT-39); Actin (forward primer, 59-
CCAACCG-CGAGAAGATGA-39; reverse primer, 5’-TCCAT-
CACGATGCCAGTG-3’). The data were normalized by the
Actin housekeeping gene detection.
Cell proliferation
For growth inhibition analysis, HCT116 cells were seeded at a
density of 3610
3 cells per well in 96-well plates. After seeding, the
growth medium was replaced with medium containing indicated
concentration of TSA. After 3 days, cell growth was measured
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (Sigma, St. Louis, MO) colorimetric method. Cell cycle
was determined by flow cytometry using a propidium iodide stain
buffer and analyzed on a BD FACS Calibur cytometer with
Cellquest software.
Measurement of Intracellular Glucose
Prior to harvesting, adherent cultures of control and TSA-
treated cells in DMEM containing 1 or 4.5 mg/ml glucose were
washed twice with cold phosphate- buffered saline (PBS) and then
lysed with ion-freeH2O for 5 min on ice. The glucose content was
measured with D-glucose measurement kit (GAHK-20, Sigma-
Aldrich, St. Louis, MO) according to the manufacturer’s protocol.
Transient transfection and luciferase activity assay
The EGFR promoter plasmid containing a firefly luciferase was
transiently transfected into HCT116 cells with Arrestin transfec-
tion reagent. Briefly, 0.9 mg of plasmid DNA, 0.1 mg of Renilla
luciferase, and 5 uL transfection reagents were mixed, and the
transfection protocol was carried out according to the manufac-
turer’s instructions (Promega). Six hours after transfection, the cells
were cultured in the normal complete medium for another 16 h.
Then, the transfected cells were subjected to luciferase assay. The
firefly luciferase activity was normalized to that of the Renilla
luciferase.
Preparation and infection of shHDAC-expressing
lentivirus
Briefly, 6 mg pCMV-dR8.91, 3 mg pMD2.G, and 9 mg pLKO-
shLuciferase, pLKO-shHDAC1, pLKO-shHDAC2 or pLKO-
shHDAC3 were cotransfected into HEK293T cells using Lipo-
fectamine 2000 (Invitrogen). The supernatants containing infec-
tious shLuciferase, shHDAC1, shHDAC2 or shHDAC3 lentivirus
were collected on day 3 after transfection and stored at 280uC.
For lentivirus infection, 2610
5 HCT116 cells were infected with
shLuciferase, shHDAC1, shHDAC2 or shHDAC3 lentivirus at a
multiplicity of infection (MOI) of 1.
Patients and specimen preparation
Specimens of tumor tissue and adjacent normal tissue of colon
were obtained from 14 patients who have been pathologically
diagnosed colon cancer and underwent surgical resection at the
National Taiwan University Hospital. Tissue specimens were
ground, then sonicated in the lysis buffer (50 mM Tris-HCl,
pH 7.4, 1 mM EGTA, 150 mM NaCl, 5% Triton X-100) with
protease inhibitors. The samples were microcentrifuged to remove
the larger debris and subjected to western analysis.
Chromatin immunoprecipitation assay
Cells were treated with 5 mM SAHA for 6 h and cross-linked
with 1.42% formaldehyde for 15 min. Cells in two 10-cm dishes
were scraped in 1 ml of cold PBS, centrifuged, and lysed in 1 mL
of IP buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 5 mM
EDTA, 0.5% Nonidet P-40, and 1% Triton X-100) containing
protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM
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pended in IP buffer and sonicated to shear chromatin. The
sonicated lysates were immunoprecipited with antibodies against
SP1, AcH3, AcH4, H3K4Me2, CBP and HDAC3, respectively
and the immune complexes were recovered with protein A-
Sepharose (Roche). The immunoprecipitated DNA and input
DNA were extracted by incubating with 100 ml of 10% Chelex
(Bio-Rad), boiling to reverse the cross-link, and centrifuging to
Figure 2. HDAC inhibitor reduced the expression of SGLT1 and decreased glucose uptake. (A) HCT116 cells were treated with 1 mM TSA
for 24, 36 or 48 hours. Whole cell lysate were prepared and subjected to western blot analysis with antibodies specific for SGLT1, EGFR and Actin. (B)
Cells were cultured in DMEM with 1 mg/ml and treated with 1 mM TSA for 24 hours. The glucose content was measured as described in material and
method (Triplicate samples were used in each group. The asterisk indicates a significant difference with p,0.05. Error bars indicate mean 6 SE.) (C)
Cells were cultured in DMEM with 1 mg/ml or 4.5 mg/ml glucose and treated with 1, 3 or 5 mM TSA for 24 hours. The glucose content was measured.
(D) Cells were cultured in DMEM with 1 mg/ml glucose and treated with 1 or 3 mM TSA. After 24 or 48 hours of treatment, the glucose was adjusted
to 4.5 mg/ml. The cell survival was measured by MTT assay after 72 hours treatment with TSA. Results were expressed as mean 6 SE of three
independent experiments performed in triplicate.
doi:10.1371/journal.pone.0018087.g002
Figure 1. HDAC inhibitor disrupted the EGF signaling in KRAS mutant colon cancer cells. (A) HCT116, SW480, WiDr and HT29 cells were
maintained in DMEM with 1 mg/ml glucose and treated with 0.1, 1, 10 mg/ml cetuximab or 1, 3, 5 mM SAHA the cell survival was measured by MTT
assay after 48 hours treatment (B) HCT116 and SW480 cells were serum-starved for 24 hours and then stimulated with 1 mM EGF for, 1, 5, 15, 30 and
60 minutes. (C) HCT116 and SW480 cells were pre-incubated with 0.5, 1 mM TSA or 5 mM SAHA for 24 hours and then stimulated with EGF for 5
minutes. (D) HCT116, SW480, A431 and MDA-MB468 cells were treated with 1 mM TSA for 24 or 36 hours Whole cell lysate was prepared and
subjected to western blot analysis with antibodies specific for phospho-Akt, phosphor-ERK, Akt and Erk.
doi:10.1371/journal.pone.0018087.g001
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the purified DNA using the following primers: A: 59-
GTGAAAAACCCCACCGTTC-39 and 59- TCTGAAGGG-
GAGCAACCTTA-39;B :5 9-AAGCTTCCGCGAGTTTCC-39
and 59- GAGGCTAAGTGTCCCACTGC-39;C :5 9- ACCCTG-
GCACAGATTTGG-39 and 59- TGAGGAGTTAATTTCCGA-
GAGG-3’; D: 59-CCAGTATTGATCGGGAGAGC-39 and 59-
TTCCTCCAGAGCCCGACT-39;E :5 9-CTGAGGAAGGAAC-
CCAAAAA-39 and 59-GGGAGGTCCTCTCAGAA AGC-39.
Statistical analysis
Triplicate experiments were performed and results are present-
ed as mean6SE. The two- tailed Student’s t test was used to
calculate the statistical significance between group
Results
HDAC inhibitors disrupt the EGF signaling via silencing
EGF receptor (EGFR) expression
To examine the antitumor effect of HDACi in colorectal
cancer, KRAS wild type (WiDR and HT29) and KRAS mutant
cells (HCT116 and SW480) were treated with SAHA or
cetuximab for 48 hours, and cell viability was measured. SAHA
reduced the survival of these cells in a dose-dependent manner
(Fig. 1A), suggesting the independence of the KRAS status on the
antitumor activity of HDACi. In contrast, cetuximab had little
effect on the cell viability (Fig. 1A). This result is consistent with
the previous study that colorectal cancer cells treated with
cetuximab were killed more efficiently by antibody-dependent
cellular cytotoxicity (ADCC) which is absent in in vitro system [19].
Since EGFR plays a significant role in CRC, the ability of its
ligand to trigger the downstream signal in KRAS mutant cells was
examined. EGF triggered both Akt and ERK phosphorylation in
HCT116 cells and induced ERK activation in SW480 cells
(Fig. 1B), indicating that KRAS mutation doesn’t fully take over
the ligand-mediated ERK activation and also impling the
significance of EGFR in KRAS mutant cells. Moreover,
pretreatment with HDAC inhibitors, TSA and SAHA, disrupted
the EGF-stimulated ERK and Akt phosphorylation in HCT116
cells and ERK phosphorylation in SW480 cells (Fig. 1C). Since
HDAC inhibitors blocked both Akt and ERK phosphorylations,
the very proximal component of EGF signaling might be targeted
by HDACi. Therefore, the expression of EGF receptor was firstly
examined. After treatment with TSA, the expression of EGFR was
decreased in HCT116, SW480, and HT29 cells. To identify
whether this is a common phenomenon, cells originated from
different organs were used. After treatment with TSA, the reduced
EGFR expression was also seen in human skin (A431) and breast
(MDA-MB468) cancer cells (Fig.1D).
HDAC inhibitors reduce the expression of SGLT1 and
decrease the intracellular glucose
In addition to EGF signaling, EGFR has been reported to be
involved in the glucose transport by associating and stabilizing the
active glucose transporter, SGLT1 [13,20]. Since the expression of
EGFR was reduced by HDACi in CRC cells, the levels of SGLT1
expression and intracellular glucose in response to HDACi were
also examined. As expected, TSA reduced the SGLT1 expression
(Fig.2A) and the intracellular glucose concentration (Fig. 2B).
Glucose replenishment retained the intracellular glucose (Fig. 2C)
and rescued cells from the TSA-induced cell death (Fig. 2D).
These data suggested that the loss of EGFR and its partner,
SGLT1, might be involved in the cytotoxic effect of HDAC
inhibitors.
Loss of EGFR is implicated in HDAC inhibitor-mediated
cytotoxicity
HDAC inhibitors are shown to exert antitumor activity by
arresting the cell cycle and triggering apoptosis [15]. Consistently,
SAHA increased sub-G1 population from 7.72% to 17.23% and
G2/M population from 16.6% to 24.4% (Fig.3A). To elucidate the
role of EGFR in the antitumor activity of HDACi, cells were
transfected with myc-EGFR and then treated with SAHA for
24 hrs. Overexpression of myc-tagged EGFR decreased the sub-
G1 population and G2/M population (Fig.3A). SAHA-induced
p21 expression was also attenuated by the ectopic expression of
EGFR (Fig.3B). These data indicated that SAHA-reduced EGFR
expression contributed to the SAHA-induced apoptosis and cell
cycle arrest.
HDACs are implicated in the transcription of EGFR
Since the amount of EGFR protein is reduced after treatment
with HDACi, the EGFR gene transcription was examined. The
mRNA level of EGFR was decreased dramatically after treatment
with TSA and SAHA (Fig.4A), suggesting HDACi transcription-
ally downregulate EGFR expression. This effect was further
confirmed by EGFR reporter assays. Our result showed that TSA
and SAHA significantly decreased the EGFR promoter activity
(Fig.4B upper panel). It has been reported that HDACi decreased
the EGFR mRNA stability in ER-negative human breast cancer
cells [21]. Therefore, the stability of EGFR mRNA was examined.
The de novo transcription was stopped by actinomycin D and the
EGFR mRNA was measured by real-time PCR. The slope of
EGFR mRNA degradation didn’t show a significant difference
between basal and TSA treatment (Fig. 4B lower panel),
suggesting that HDACi didn’t affect the degradation of EGFR
mRNA in colorectal cancer cells. To further elucidate the
involvement of HDACs in the transcription of EGFR, myc-tagged
HDAC1, HDAC2 or HDAC3 was ectopically expressed in
HCT116 cells, and EGFR mRNA was measured by RT-PCR.
An increase of EGFR mRNA was found in all these HDAC-
expressing cells (Fig. 4C upper panel). Conversely, knockdown of
HDAC1, HDAC2 or HDAC3 by shRNA reduced the expression
of EGFR protein (Fig.4C lower panel). These data indicated that
class I HDACs are crucial for EGFR expression. The positive
correlation between EGFR and HDAC3 expression was also
observed in fourteen pairs of human colon tumor and adjacent
normal tissues (Fig. 4D).
SP1 is essential for EGFR transcription and HDAC
inhibitor disturbs the binding of SP1 to EGFR promoter
There are several SP1 binding sites on the EGFR promoters
and our previous studies showed that HDACi affects the binding
of SP1 to ADAMTS1or p21 promoters [22,23]. Therefore, SP1
Figure 3. Loss of EGFR contributed to HDAC inhibitor-mediated antitumor effects. (A) HCT116 cells were transfected with Myc-EGFR as
well as its vector control and transfected cells were treated with 5 mM SAHA for 24 hours. Cells were fixed by 70% ethanol and stained with
propidium iodide, and fraction of cell cycle was analyzed by flow cytometer. (B) HCT116 cells were transfected with Myc-EGFR as well as its vector
control and the transfected cells were treated with 5 mM SAHA for 24 hours. Whole cell lysate were prepared and subjected to western blot using Ab
specific for EGFR, Myc, p21 and tubulin.
doi:10.1371/journal.pone.0018087.g003
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Indeed, inhibition of SP1 by mithramycin A (MTM) and siRNA
significantly decreased the EGFR expression (Fig.5A). Further-
more, MTM drastically reduced the EGFR promoter activity
(Fig.5B), indicating the critical role of SP1 in EGFR gene
transcription. The binding of SP1 to the EGFR promoter is
Figure 4. HDAC is involved in the regulation of EGFR transcription. (A) HCT116 cells were treated with 1 mM TSA or 5 mM SAHA for 1 and
8 hours. Total RNA (2 mg) was used for RT-PCR and Real-time PCR as described. (B, upper panel) Cells were treated with 1 mM TSA or 5 mM SAHA for
6 hour, then transfected with EGFR-Luc. Luciferase activities were measured as described under ‘‘Material and Method’’. (B, lower panel) Cells were
treated with 1 mM TSA for 4 h before RNA synthesis was stopped by actinomycin D (5 mg/ml) for 0, 2, 4 or 6 h. RNA was prepared at indicated time
points following the addition of actinomycin D and levels of EGFR mRNA were measured by real-time PCR. (C, upper panel) Cells were transiently
transfected with Myc-tagged HDAC1, 2 or 3, respectively and total RNA (2 mg) was used for RT-PCR to detect the EGFR mRNA level. (C, lower panel)
Cells were transfected with shLuc, shHDAC1, shHDAC2 or shHDAC3 by lentivirus as described under ‘‘Material and Method’’. Cell lysates were
harvested on day 5 after transfection and then subjected to western blot analysis with antibodies specific for EGFR, HDAC1, HDAC2 and HDAC3. (D)
Lysates of paired human normal and malignant colon tissues were subjected to western blotting using anti-EGFR, anti-HDAC3 and anti-Actin
antibodies. The correlation between EGFR and HDAC3 expression levels was evaluated by correlation coefficients.
doi:10.1371/journal.pone.0018087.g004
Figure 5. SP1 is essential for the EGFR transcription. (A) Cells were treated with 1 mM Mithramycin A (MTM) for 18 or 36 hours, then the total
cell lysate were prepared. Cells were transfected with 0, 400 or 800 pmole SP1 siRNA, then the total cell lysates were prepared and subjected to
western blot analysis with antibodies specific for EGFR and SP1. (B) Cells were transfected with EGFR-Luc and then treated with 0.1, 1 or 5 mM
Mithramycin A (MTM) for 16 hours. Luciferase activities were measured as described under ‘‘Material and Method’’. The results were normalized to
the Renilla luciferase activity and expressed as the mean 6 SE. For three independent experiments performed in triplicate.
doi:10.1371/journal.pone.0018087.g005
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Five primer pairs (A, B, C, D and E) were designed to evenly
cover the regions (21,200 to +1,000 bps) around transcription
start site (Fig.6A). Our data showed that the binding of SP1 to
r e g i o n sCa n dDw a ss i g n i f i c a n t l ydecreased after treatment with
SAHA (Fig.6B). Furthermore, the acetylation of Histone H3 and
H4 on EGFR promoter was largely reduced, especially in the
regions nearby transcription start site (Fig.6B). The status of
histone methylation such as H3K4Me2, H3K9Me3 and
H3K27Me3 was also examined. SAHA didn’t change the
residence of these methylation markers on EGFR promoter
despite of enriched H3K4Me2 was found (Fig.6B and data not
shown). Since the acetylation of histone H3 and H4 dropped
dramatically after HDAC inhibition, the occupancy of histone
acetyltransferase (HAT) or HDAC on EGFR promoter was
examined. Our result showed that the recruitment of CBP to
region D was significantly decreased by SAHA (Fig.6B).
Interestingly, the binding of HDAC3 to the region D was
attenuated, too (Fig.6B). These data showed the dissociation of
SP1, CBP and HDAC3 from EGFR promoter at the same time
(Fig.7), implying that these proteins may influence each other
and affect their binding to the EGFR promoter.
Discussion
EGFR and HDAC have been reported to be overexpressed in
colorectal and various cancers [1,15]. However, their relationship
is not well-characterized. In this study, we showed that HDAC
inhibitors (HDACi) were able to disrupt the EGF-signaling in
colon cancer cells. EGFR expression in these cells as well as other
origins such as epidermoid (A431) and breast (MDA-MB468) was
decreased by HDACi, suggesting the potential of HDACi to treat
EGFR overexpressing cancers. HDACi also reduced the expres-
sion of an active glucose transporter, SGLT1, and thereby
suppressed the glucose uptake of colon cancer cells. More in-
depth, we showed that SAHA induced the dissociation of SP1/
CBP/HDAC3 from the regions around EGFR transcription start
site where the histones became hypoacetylated. Our data indicated
that the HDAC inhibitors could serve as a single agent to block
EGFR and HDAC, two critical factors in CRC cells, and may
provide a more effective therapy for a broader range of indication.
Most solid tumors reside in a hypoxic environment and prefer
the anaerobic glycolysis rather than aerobic glycolysis, converting
glucose to lactate and produce fewer ATP with less oxygen
consumption. Therefore, the glucose uptake is frequently en-
Figure 6. The epigenetic alteration on EGFR promoter. (A) Illustration of the EGFR promoter and the ChIP primer. (B) Cells were treated with
SAHA for 8 hours, then fixed, sonicated and subjected to Chromatin Immunoprecipitation using Ab specific against SP1 and acetylated histone H3.
Histone H4 acetylation H3K4 dimethylation, CBP and HDAC3 on EGFR promoter was measured by ChIP assays as described under ‘‘Material and
Method’’.
doi:10.1371/journal.pone.0018087.g006
Figure 7. Schematic diagram of EGFR promoter in the basal state or treatement with HDACi. In the basal state, HDAC3, CBP and SP1 were
both recruited to the promoter region and responsible for the transcription of EGFR (A). While treated with HDACi, the complex of HDAC3, CBP and
SP1 were disrupted and dispersed from EGFR promoter, leading to the inactivation of EGFR transcription (B).
doi:10.1371/journal.pone.0018087.g007
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as GLUT1 and SGLT1 [24]. Unlike GLUT1 that transports
glucose passively, SGLT1 uses the electro-chemical sodium
gradient to transport glucose against the internal concentration
gradient. SGLT1 is expressed in human colon cancers, pancreatic
cancer, lung cancer and neoplastic lesions of head and neck [25–
29]. It is found to be stabilized by EGFR, and knockdown of
EGFR decreases the SGLT1 expression and glucose uptake [13].
Our data also showed that HDACi-mediated loss of EGFR, and
the concurrent reduction of SGLT1 expression and glucose uptake
would eliminate the overall pro-survival functions of EGFR.
Several studies show the inhibitory effect of HDACi on EGFR
expression in human cancers. For example, FK-228, a depsipep-
tide HDAC inhibitor, is reported to decrease the expression of
EGFR in lung cancer cells [30]. SAHA decreases the levels of
EGFR in ER-negative breast cancer cells via mRNA destabilzai-
ton [21]. More recently, inhibition of HDAC6 is found to enhance
the endocytosis of EGFR through increasing tubulin acetylation
[31,32]. In this study, we demonstrated that both EGFR mRNA
and its promoter activity were inhibited by HDAC inhibitors in
colon cancer cells, indicating that the de novo synthesis of EGFR
was transcriptionally inhibited. EGFR promoter is characterized
with GC-rich, and TATA-less, and harbors multiple specificity
protein 1 (Sp1) binding sites [33]. In addition to SP1, several
transcription factors, such as AP-1, p53 and c-Jun, also participate
in the EGFR transcription [34]. SP1 has been reported to regulate
the basal EGFR promoter activity [35]. We showed that inhibition
or knockdown of SP1 could decrease the promoter activity and
protein expression of EGFR, emphasizing its crucial role in EGFR
expression.
SP1 has been reported to be regulated by several post-
translational modifications, including phosphorylation, acetyla-
tion, ubiquitination and sumoylation [36]. It is acetylated by p300
and deacetylated by HDAC [37]. Although acetylated SP1 could
increase the transcription of GC-box-dependent genes [37],
accumulating data also show that acetylation of SP1 decrease
the its transcriptional activity. For example, SP1 acetylation by
HDACi reduces its ability to regulate 12(s)-lipooxygenase (12S-
LOX) expression. Ectopic expression of SP1 mutant, which cannot
be acetylated at lysine 703, increases 12S-LOX transcription, and
deacetylation of SP1 is also required for the transcription of COX-
2 [38,39]. Our previous studies show that HDACi affects the
binding of SP1 to ADAMTS1 promoter and the association of SP1
and CBP on p21 promoter [22,23]. SP1 on EGFR promoter
might be affected by HDACi as well. Indeed, SP1 was dissociated
from EGFR promoter after treatment with HDACi, implying that
acetylation may decrease the binding of SP1 to the EGFR
promoter. Surprisingly, the histones on EGFR promoter became
hypoacetylated. This could be explained by the concurrent
dissociation of CBP, the histone acetyltransferase (HAT).
HDACi is reported to induce G2/M growth arrest as well as
G0/G1 arrest in colorectal cancer cells, and the HDACi-mediated
growth arrest consistently involves p21 induction [40–43]. In
HCT116 cells, p21 is induced and the cell cycle is arrested in G2/
M phase by silencing class I HDACs, especially HDAC3 [17].
Consistently, we found that SAHA induced p21 and G2/M arrest
and re-expression of EGFR could alleviate these events. HDAC3
has been reported to be maximally expressed in the proliferative
compartment in mouse colon. Knockdown of HDAC3 induced a
greater magnitude of G2/M and S phase arrest than that of
HDAC1/2, suggesting that HDAC3 is more significant than
HDAC1/2 in colon cell proliferation [17]. HDAC3 is a
component of the NCoR-SMRT co-repressor complex, which is
distinct from repressor complexes containing HDAC1 and
HDAC2 (Sin3A and NuRD) [44], indicating the specific roles of
HDAC isoform in gene repressing. In contrast, knockdown of
HDAC1, 2 or 3 decreased the EGFR expression in varying
degree, indicating that they share functional redundancy on
promoting EGFR transcription. Ectopic express HDAC3 induced
a greater magnitude of EGFR mRNA and a positive correlation
between EGFR and HDAC3 expression in colon cancer patients.
Therefore, HDAC3 may be most essential in EGFR transcription.
Association of HDACs with gene promoters are traditionally
considered to repress transcription and HDAC is thought to
reactivate the silenced genes [45]. However, HDACi is also
reported to decrease the expression of thymidylate synthase,
vascular endothelial growth factor (VEGF), basic fibroblast growth
factor (bFGF) and endothelial nitric oxide synthase (eNOS) [46–
48]. It is suggested that gene transcription primed by H3K4
methylation requires the dynamic cycle of histone acetylation and
deacetylation by transient HAT/HDAC binding [49]. In this
study, we found that EGFR promoter was enriched with H3K4 di-
methylation, suggesting that EGFR gene transcription may be
primed by H3K4 methylation. HDAC3 and CBP were both
associated with EGFR promoter and concurrently dissociated after
treatment with HDACi, implying that dynamic HAT/HDAC
binding is occurred. Since CBP and HDAC3 are unable to directly
bind gene promoter, SP1 may serve as a bridge between CBP/
HDAC3 and EGFR promoter (Fig. 6A). HDACi may induce SP1
acetylation and leads to its dissociation from EGFR promoter,
which disrupts the dynamic binding of HDAC3 and CBP (Fig. 6B).
Taken together, our results showed that the SP1, HDAC3 and
CBP were all dissociated from EGFR promoter after SAHA
treatment, suggesting their functional relevance on EGFR
transcription.
It has been reported that HDAC inhibitors synergize with 5-FU
in vitro and in vivo to treat colon cancer through downregulation of
thymidylate synthase, the 5-FU target enzyme [46]. Combination
of 5-FU with SAHA has recently entered phase I/II trial to treat
CRC [18,50]. Inhibition of MAPK and Akt signaling by AEE788,
a multiple receptor tyrosine kinases inhibitor, synergistically
potentiates HDAC-induced apoptosis in a broad spectrum of
cancer cell lines [51]. Recently, a new compound, CUDC-101,
which inhibit the activity of both EGFR and HDAC, is
demonstrated to have powerful anticancer activity [52]. These
reports strengthen the rationale of concurrent inhibition of EGFR
and HDAC in cancer therapy. In this study, we showed that
HDAC inhibitor alone is able to block EGFR transcription as well
as HDAC, and may provide a hint for superior strategy of
colorectal cancer therapy.
Author Contributions
Conceived and designed the experiments: C-WC M-SW C-CC. Performed
the experiments: C-WC. Analyzed the data: C-WC W-CH C-CC.
Contributed reagents/materials/analysis tools: M-SW W-CH. Wrote the
paper: C-WC C-CC.
References
1. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, et al. (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:
2–16.
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory
metastaticcolorectalcancer.TheNewEnglandjournalofmedicine351:337–345.
HDACs Are Implicated in EGFR Overexpression
PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e180873. Rajpal S, Venook AP (2006) Targeted therapy in colorectal cancer. Clinical
advances in hematology & oncology: H&O 4: 124–132.
4. Amado RG, Wolf M, Peeters M, Van Cutsem , Siena S, et al. (2008) Wild-
type KRAS is required for panitumumab efficacy in patients with metastatic
colorectal cancer. Journal of clinical oncology: official journal of the American
Society of Clinical Oncology 26: 1626–1634.
5. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, et al. (2009)
Cetuximab and chemotherapy as initial treatment for metastatic colorectal
cancer. N Engl J Med 360: 1408–1417.
6. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, et al. (2009)
Genetic prognostic and predictive markers in colorectal cancer. Nature reviews
Cancer 9: 489–499.
7. Banck MS, Grothey A (2009) Biomarkers of Resistance to Epidermal Growth
Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal
Cancer. Clinical cancer research: an official journal of the American Association
for Cancer Research 15: 7492–7501.
8. Linardou H, Papadimitriou CA, Dahabreh IJ, Kanaloupiti D, Siannis F, et al.
(2008) Assessment of somatic k-RAS mutations as a mechanism associated with
resistance to EGFR-targeted agents: a systematic review and meta-analysis of
studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
The Lancet Oncology 9: 962–972.
9. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, et al. (1995)
Epithelial immaturity and multiorgan failure in mice lacking epidermal growth
factor receptor. Nature 376: 337–341.
10. Luetteke NC, Phillips HK, Qiu TH, Copeland NG, Earp HS, et al. (1994) The
mouse waved-2 phenotype results from a point mutation in the EGF receptor
tyrosine kinase. Genes & Development 8: 399–413.
11. Ewald J (2003) Ligand- and kinase activity-independent cell survival mediated by
the epidermal growth factor receptor expressed in 32D cells. Experimental Cell
Research 282: 121–131.
12. Harari PM, Huang S-M (2004) Combining EGFR inhibitors with radiation or
chemotherapy: will preclinical studies predict clinical results? International
journal of radiation oncology, biology, physics 58: 976–983.
13. Fidler IJ, Weihua Z, Tsan R, Huang W-C, Wu Q, et al. (2008) Survival of
cancer cells is maintained by EGFR independent of its kinase activity. Cancer
cell 13: 385–393.
14. Ritter CA, Arteaga CL (2003) The epidermal growth factor receptor-tyrosine
kinase: a promising therapeutic target in solid tumors. Seminars in oncology 30:
3–11.
15. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone
deacetylase inhibitors. Nature reviews Drug discovery 5: 769–784.
16. Mariadason JM (2008) HDACs and HDAC inhibitors in colon cancer.
Epigenetics: official journal of the DNA Methylation Society 3: 28–37.
17. Wilson AJ, Byun D-S, Popova N, Murray LB, L’Italien K, et al. (2006) Histone
deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation
and p21 expression and are deregulated in human colon cancer. The Journal of
biological chemistry 281: 13548–13558.
18. Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, Labonte MJ, et al. (2010) A
phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with
metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
Cancer chemotherapy and pharmacology. pp 979–988.
19. Levy EM, Sycz G, Arriaga JM, Barrio MM, von Euw EM, et al. (2009)
Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane
expression in colon cancer cells. Innate Immun 15: 91–100.
20. Engelman JA, Cantley LC (2008) A sweet new role for EGFR in cancer. Cancer
cell 13: 375–376.
21. Zhou Q, Shaw PG, Davidson NE (2009) Inhibition of histone deacetylase
suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-
negative human breast cancer cells. Breast Cancer Res Treat 117: 443–451.
22. Chou C-W, Chen C-C (2008) HDAC inhibition upregulates the expression of
angiostatic ADAMTS1. FEBS Letters 582: 4059–4065.
23. Lin Y-C, Lin J-H, Chou C-W, Chang Y-F, Yeh S-H, et al. (2008) Statins
increase p21 through inhibition of histone deacetylase activity and release of
promoter-associated HDAC1/2. Cancer research 68: 2375–2383.
24. Ganapathy V, Thangaraju M, Prasad PD (2009) Nutrient transporters in cancer:
relevance to Warburg hypothesis and beyond. Pharmacology & therapeutics
121: 29–40.
25. Casneuf VF, Fonteyne P, {Van Damme} N, Demetter P, Pauwels P, et al. (2008)
Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to
survival. Cancer investigation 26: 852–859.
26. Mahraoui L, Rodolosse A, Barbat A, Dussaulx E, Zweibaum A, et al. (1994)
Presence and differential expression of SGLT1, GLUT1, GLUT2, GLUT3 and
GLUT5 hexose-transporter mRNAs in Caco-2 cell clones in relation to cell
growth and glucose consumption. Biochem J 298 Pt 3: 629–633.
27. Blais A (1991) Expression of Na(+)-coupled sugar transport in HT-29 cells:
modulation by glucose. Am J Physiol 260: C1245–1252.
28. Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N (2001) SGLT gene
expression in primary lung cancers and their metastatic lesions. Jpn J Cancer
Res 92: 874–879.
29. Helmke BM, Reisser C, Idzko M, Dyckhoff G, Herold-Mende C (2004)
Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and
neck. Oral Oncol 40: 28–35.
30. Yu XD, Wang SY, Chen GA, Hou CM, Zhao M, et al. (2007) Apoptosis
induced by depsipeptide FK228 coincides with inhibition of survival signaling in
lung cancer cells. Cancer J 13: 105–113.
31. Gao YS, Hubbert CC, Yao TP (2010) The microtubule-associated histone
deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR)
endocytic trafficking and degradation. J Biol Chem 285: 11219–11226.
32. Deribe YL, Wild P, Chandrashaker A, Curak J, Schmidt MH, et al. (2009)
Regulation of epidermal growth factor receptor trafficking by lysine deacetylase
HDAC6. Sci Signal 2: ra84.
33. Brandt B, Meyer-Staeckling S, Schmidt H, Agelopoulos K, Buerger H (2006)
Mechanisms of egfr gene transcription modulation: relationship to cancer risk
and therapy response. Clinical cancer research: an official journal of the
American Association for Cancer Research 12: 7252–7260.
34. Johnson AC, Murphy BA, Matelis CM, Rubinstein Y, Piebenga EC, et al. (2000)
Activator protein-1 mediates induced but not basal epidermal growth factor
receptor gene expression. Molecular medicine (Cambridge, Mass) 6: 17–27.
35. Kageyama R, Merlino GT, Pastan I (1988) Epidermal growth factor (EGF)
receptor gene transcription. Requirement for Sp1 and an EGF receptor-specific
factor. The Journal of biological chemistry 263: 6329–6336.
36. Waby JS, Bingle CD, Corfe BM (2008) Post-translational control of sp-family
transcription factors. Current genomics 9: 301–311.
37. Koshiji M, To KKW, Hammer S, Kumamoto K, Harris AL, et al. (2005) HIF-
1a Induces Genetic Instability by Transcriptionally Downregulating MutSa
Expression. Molecular Cell 17: 793–803.
38. Chen C-J, Chang W-C, Chen B-K (2008) Attenuation of c-Jun and Sp1
expression and p300 recruitment to gene promoter confers the trichostatin A-
induced inhibition of 12(S)-lipoxygenase expression in EGF-treated A431 cells.
European journal of pharmacology 591: 36–42.
39. Tong X, Yin L, Giardina C (2004) Butyrate suppresses Cox-2 activation in colon
cancer cells through HDAC inhibition. Biochemical and biophysical research
communications 317: 463–471.
40. Kobayashi H, Tan EM, Fleming SE (2003) Sodium butyrate inhibits cell growth
and stimulates p21WAF1/CIP1 protein in human colonic adenocarcinoma cells
independently of p53 status. Nutr Cancer 46: 202–211.
41. Xu WS, Perez G, Ngo L, Gui CY, Marks PA (2005) Induction of polyploidy by
histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res 65:
7832–7839.
42. Heerdt BG, Houston MA, Augenlicht LH (1997) Short-chain fatty acid-initiated
cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial
function. Cell Growth Differ 8: 523–532.
43. Schwartz B, Avivi-Green C, Polak-Charcon S (1998) Sodium butyrate induces
retinoblastoma protein dephosphorylation, p16 expression and growth arrest of
colon cancer cells. Mol Cell Biochem 188: 21–30.
44. Jepsen K, Rosenfeld MG (2002) Biological roles and mechanistic actions of co-
repressor complexes. J Cell Sci 115: 689–698.
45. Berger SL (2007) The complex language of chromatin regulation during
transcription. Nature 447: 407–412.
46. Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD (2009) Histone
deacetylase inhibitors suppress thymidylate synthase gene expression and
synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer 125:
463–473.
47. Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, et al. (2003) Antitumor
efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on
expression of angiogenesis factors. Biochem Pharmacol 66: 897–906.
48. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, et al. (2002) Inhibitors of
histone deacetylation downregulate the expression of endothelial nitric oxide
synthase and compromise endothelial cell function in vasorelaxation and
angiogenesis. Circ Res 91: 837–844.
49. Wang Z, Zang C, Cui K, Schones DE, Barski A, et al. (2009) Genome-wide
mapping of HATs and HDACs reveals distinct functions in active and inactive
genes. Cell 138: 1019–1031.
50. Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, et al. (2009) A phase I,
pharmacokinetic and pharmacodynamic study on vorinostat in combination
with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory
colorectal cancer. Clinical cancer research: an official journal of the American
Association for Cancer Research 15: 3189–3195.
51. Yu C, Friday BB, Lai JP, McCollum A, Atadja P, et al. (2007) Abrogation of
MAPK and Akt signaling by AEE788 synergistically potentiates histone
deacetylase inhibitor-induced apoptosis through reactive oxygen species
generation. Clin Cancer Res 13: 1140–1148.
52. Lai CJ, Bao R, Tao X, Wang J, Atoyan R, et al. (2010) CUDC-101, a
multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor,
and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Cancer Res 70: 3647–3656.
HDACs Are Implicated in EGFR Overexpression
PLoS ONE | www.plosone.org 12 March 2011 | Volume 6 | Issue 3 | e18087
  E